Literature DB >> 15172783

Learning from Philip Morris: Japan Tobacco's strategies regarding evidence of tobacco health harms as revealed in internal documents from the American tobacco industry.

Kaori Iida1, Robert N Proctor.   

Abstract

Japan is in the midst of a rapid increase in tobacco-related disease mortality, following the rapid growth of smoking after WWII. Stomach cancer was the country's leading cause of cancer death for most of the 20th century, until lung cancer took over this position in 1993. Cigarettes are the major cause of lung cancer in Japan, but the country's leading manufacturer, Japan Tobacco, two thirds of which is owned by the Japanese government, continues to question whether tobacco is a major cause of disease and death. Japanese courts do not have the power to subpoena a company's internal records, which has made it difficult to document Japan Tobacco's strategies concerning tobacco and health. Our interpretation of online archives of internal documents from American tobacco companies, however, is that Japan Tobacco has long known about the potential health risks involved in smoking and has sought to obstruct effective tobacco control. Beginning in the mid-1980s, these efforts were often co-ordinated with American tobacco manufacturers. The documentary evidence shows that cigarette manufacturer Philip Morris in particular assisted with and sometimes also supervised Japan Tobacco's actions and statements on smoking and health. In one instance, data gathered for an article published by the Japan Public Monopoly Corporation (Japan Tobacco's predecessor) were deliberately altered to lower the reported value of a hazard indicator (nicotine concentration in the air). International collaboration has made it easier for companies such as Japan Tobacco to develop effective anti-antismoking strategies. Evidence of such global industry collaborations might grow as lawsuits begin to be filed in other nations.

Entities:  

Mesh:

Year:  2004        PMID: 15172783     DOI: 10.1016/S0140-6736(04)16310-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

Review 1.  Asian herbal-tobacco cigarettes: "not medicine but less harmful"?

Authors:  Aiyin Chen; Stanton Glantz; Elisa Tong
Journal:  Tob Control       Date:  2007-04       Impact factor: 7.552

Review 2.  ARTIST (Asian regional tobacco industry scientist team): Philip Morris' attempt to exert a scientific and regulatory agenda on Asia.

Authors:  E K Tong; S A Glantz
Journal:  Tob Control       Date:  2004-12       Impact factor: 7.552

3.  Analysis of a tobacco vector and its actions in china: the activities of japan tobacco.

Authors:  Peisen He; Takeaki Takeuchi; Eiji Yano
Journal:  Tob Induc Dis       Date:  2010-10-27       Impact factor: 2.600

4.  Risk factor effects and total mortality in older Japanese men in Japan and Hawaii.

Authors:  Robert D Abbott; Hirotsugu Ueshima; Atsushi Hozawa; Tomonori Okamura; Takashi Kadowaki; Katsuyuki Miura; Nagako Okuda; Yasuyuki Nakamura; Akira Okayama; Yoshikuni Kita; Beatriz L Rodriguez; Katsuhiko Yano; J David Curb
Journal:  Ann Epidemiol       Date:  2008-12       Impact factor: 3.797

5.  Conveying misinformation: Top-ranked Japanese books on tobacco.

Authors:  Yuko Kanamori; Ruth E Malone
Journal:  Tob Induc Dis       Date:  2011-01-24       Impact factor: 2.600

6.  The globalisation strategies of five Asian tobacco companies: An analytical framework.

Authors:  Kelley Lee; Jappe Eckhardt
Journal:  Glob Public Health       Date:  2016-11-25

7.  'The industry must be inconspicuous': Japan Tobacco's corruption of science and health policy via the Smoking Research Foundation.

Authors:  Kaori Iida; Robert N Proctor
Journal:  Tob Control       Date:  2018-02-04       Impact factor: 7.552

8.  Industry Speed Bumps on Local Tobacco Control in Japan? The Case of Hyogo.

Authors:  Keiko Yamada; Nagisa Mori; Mina Kashiwabara; Sakiko Yasuda; Rumi Horie; Hiroshi Yamato; Loic Garçon; Francisco Armada
Journal:  J Epidemiol       Date:  2015       Impact factor: 3.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.